Uncategorized

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Published

on

The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version